Eeles et al. reply:
We recently conducted a genome-wide association study (GWAS) using data from 1,854 individuals with clinically detected (not PSA screened) prostate cancer diagnosed at <60 years or with a family history of the disease, and 1,894 populationscreened controls with a prostate-specific antigen (PSA) of <0.5ng/ml (ref. 1). These were analyzed for 541,129 SNPs using the Illumina Infinium platform. We then evaluated putative associations using a further 3,268 cases and 3,366 controls. After these two stages, associations at seven loci, on chromosomes 3,6,7,10,11,19 and X, reached genome-wide levels of significance (P = 2.7 × 10 −8 to P = 8.7 × 10 −29 ). The SNP rs2735839 on chromosome 19 lies between two kallikreins, PSA (encoded by KLK3) and hK2 (encoded by KLK2). It was associated with a per allele OR for prostate cancer of 0.83 (95% CI = 0.75-0.91; P trend in stage 2 = 0.0002; P trend overall = 2 × 10 −18 ). We also showed that rs2735839 was strongly associated with PSA level, in the direction consistent with the disease association (per allele rise in geometric mean PSA = 1.12., P = 6 × 10 −8 ).
Ahn et al. 2 analyzed 24 tag SNPs in the kallikrein region on chromosome 19 (to include KLK1, KLK2, KLK3 and KLK15) in five studies and found that none showed a significant association with prostate cancer risk. They also confirmed the association between several SNPs, including rs2735839, and PSA level. They raise the possibility that the association found with prostate cancer risk in our study may reflect the selection of subjects on the basis of PSA levels rather than a causal relationship with prostate cancer risk.
It is clear that the selection of controls in stage 1 of our study for low PSA levels did influence the association in stage 1. This is reflected in the minor allele frequency for rs2735839, which is 21.1% in the stage 1 controls, compared with 14-15% in the UK 1958 birth cohort and the CGEMS study (which included both males and females). However, the controls in stage 2 were not highly selected for PSA level. The only selection was to exclude controls with PSA levels of >10 and to require a negative prostatic biopsy if the PSA was >4. The MAF in the stage 2 controls (15.2%) is similar to that in other control populations and indicates that any selection bias at this stage was minimal.
To further evaluate the evidence for this association, we have undertaken an analysis of rs2735839 (together with SNPs at the other loci identified in our GWAS) in 13 further case-control studies as part of the PRACTICAL Consortium. These studies comprise 7,370 prostate cancer cases and 5,342 controls. The estimated per allele OR for prostate cancer associated with rs2735839 was 0.89 (95% CI = 0.83-0.95; P = 0.0007), very close to our original estimate 3 . There was no evidence of heterogeneity in the OR estimates among studies (Fig. 1) . We also note that when data from the five CGEMS studies are combined, the per allele OR is also notably similar (per allele OR = 0.90, 95% CI =0.83-0.90; P = 0.01), although this was not formally significant using the 4-degree-of-freedom test given by Ahn et al. 2 . If the results from our stage 2, PRACTICAL and CGEMS are combined, the overall evidence of association reaches genome-wide levels of significance (P < 10 −8 ), demonstrating that, even disregarding our stage 1 result, the association is unlikely to be due to chance. The overall effect size, although modest, is comparable to that seen for other cancer-associated loci.
None of the control series used in PRACTICAL or in CGEMS involved selection for PSA level, and for this reason and those given above, the association seems unlikely to be driven purely by control selection. Selection bias related to case ascertainment is an alternative possible explanation. We excluded from our GWAS any cases identified through PSA screening, and several of the studies included in PRACTICAL are drawn from populations where PSA screening has not been used (for example, the study from Finland). Thus, the association is unlikely to be due to PSA screening for asymptomatic disease. PSA testing is, however, also used in the process of diagnosis of symptomatic disease. This raises the possibility of a more subtle bias, in that some cases may have raised PSA related to their genotype but not related to their disease. Whether or not this potential bias is significant could be resolved using genotyping in studies based on biopsy of whole populations not driven by the PSA level 4 or studies where mortality is the endpoint.
Conversely, there are plausible biological grounds for believing that the association with KLK polymorphisms may be causal. For example, polymorphisms in the promoter of KLK3 are associated with alterations in androgen receptor binding 5 . Moreover, it is known that PSA level is a long-term predictor of prostate cancer risk 6 , and it is plausible that determinants of PSA level, including genetic determinants, may influence prostate cancer risk. Odds ratio Figure 1 Forest plot giving the per-allele odds ratios between rs2735839 and prostate cancer for each study in PRACTICAL. Horizontal lines represent 95% confidence intervals. The area of each square is inversely proportional to the variance of the log(odds ratio). The diamond represents the combined odds ratio and 95% confidence interval, estimated by logistic regression adjusted for study.
